Form 4: aTyr Pharma CEO Sanjay Shukla Acquires 20,000 Shares
SEC Form 4 Filing
aTyr Pharma's CEO, Sanjay Shukla, recently purchased 20,000 shares of the company's common stock at an average price of $1.807 per share.
Summary
- On May 31, 2024, Sanjay Shukla, the President and CEO of aTyr Pharma Inc., acquired 20,000 shares of common stock.
- The shares were purchased at a weighted average price of $1.807 per share, with individual prices ranging from $1.77 to $1.86.
- Following this transaction, Shukla directly owns 136,548 shares of aTyr Pharma.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive signal, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of the stock purchase transaction. |
| 06/03/2024 | Date of the signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.